CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers
- 2 December 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 4 (1), 34-39
- https://doi.org/10.1038/sj.tpj.6500218
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4Clinical Pharmacology & Therapeutics, 1999
- Expression of Cytochrome P450 3A7 inEscherichia coli:Effects of 5′ Modification and Catalytic Characterization of Recombinant Enzyme Expressed in Bicistronic Format with NADPH-Cytochrome P450 ReductaseArchives of Biochemistry and Biophysics, 1997
- Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver MicrosomesArchives of Biochemistry and Biophysics, 1996
- Midazolam is metabolized by at least three different cytochrome P450 enzymesBritish Journal of Anaesthesia, 1994
- The role of individual human cytochrpmes P450 in drug metabolism and clinical responseTrends in Pharmacological Sciences, 1992
- Interaction of citrus juices with felodipine and nifedipineThe Lancet, 1991
- Nonlinear first-pass metabolism of nifedipine in healthy subjectsXenobiotica, 1991
- The pharmacokinetics of oral nifedipine‐a population study.British Journal of Clinical Pharmacology, 1988
- The first pass metabolism of nifedipine in man.British Journal of Clinical Pharmacology, 1984
- Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urineJournal of Chromatography B: Biomedical Sciences and Applications, 1984